These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 23171115

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Thrombopoietin-receptor agonists for immune thrombocytopenia.
    Jansen AJ, Swart RM, te Boekhorst PA.
    N Engl J Med; 2011 Dec 08; 365(23):2240-1. PubMed ID: 22150056
    [No Abstract] [Full Text] [Related]

  • 23. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
    Horikoshi A, Tsukuda J, Abe R, Fujiwara N, Ito E, Takaku T.
    Rinsho Ketsueki; 2016 May 08; 57(5):638-41. PubMed ID: 27263792
    [Abstract] [Full Text] [Related]

  • 24. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R, de Knegt RJ, Veldt BJ.
    Drugs; 2015 Nov 08; 75(17):1981-92. PubMed ID: 26501978
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.
    Lancet Haematol; 2015 Oct 08; 2(10):e417-26. PubMed ID: 26686043
    [Abstract] [Full Text] [Related]

  • 29. Stable Liver Function during Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease.
    Kurokawa T, Murata S, Ohkohchi N.
    Tohoku J Exp Med; 2016 Dec 08; 240(4):277-279. PubMed ID: 27928110
    [Abstract] [Full Text] [Related]

  • 30. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
    Trautmann K, Jakob C, von Grünhagen U, Schleyer E, Brümmendorf TH, Siegert G, Ehninger G, Platzbecker U.
    Thromb Haemost; 2012 Aug 08; 108(2):397-8. PubMed ID: 22739569
    [No Abstract] [Full Text] [Related]

  • 31. Current status of thrombopoietic agents.
    Rhodes E, Stasi R.
    Expert Rev Hematol; 2010 Apr 08; 3(2):217-25. PubMed ID: 21083464
    [Abstract] [Full Text] [Related]

  • 32. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.
    Lancet; 2015 Oct 24; 386(10004):1649-58. PubMed ID: 26231455
    [Abstract] [Full Text] [Related]

  • 33. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB, Keating GM, Garnock-Jones KP.
    Drugs; 2016 May 24; 76(8):869-78. PubMed ID: 27151255
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.
    Lancet Haematol; 2015 Aug 24; 2(8):e315-25. PubMed ID: 26688484
    [Abstract] [Full Text] [Related]

  • 38. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB.
    Lancet; 2011 Jan 29; 377(9763):393-402. PubMed ID: 20739054
    [Abstract] [Full Text] [Related]

  • 39. Eltrombopag for thrombocytopenic patients with chronic HCV infection.
    Maan R, Veldt BJ, Janssen HL.
    Gastroenterology; 2014 Jul 29; 147(1):254-5. PubMed ID: 24877871
    [No Abstract] [Full Text] [Related]

  • 40. Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
    Carrabba M, Barcellini W, Fabio G.
    J Clin Immunol; 2016 Jul 29; 36(5):434-6. PubMed ID: 27072856
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.